PubRank

Patrizia Ferrera

Author PubWeight™ 36.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer 2011 1.65
2 Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008 1.04
3 Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009 1.00
4 Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 2004 0.99
5 Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004 0.98
6 Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer 2008 0.97
7 Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004 0.97
8 Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005 0.96
9 The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care 2010 0.96
10 High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage 2008 0.96
11 A model of acute symptom control unit: Pain Relief and Palliative Care Unit of La Maddalena Cancer Center. Support Care Cancer 2002 0.96
12 Opioid escalation in patients with cancer pain: the effect of age. J Pain Symptom Manage 2006 0.95
13 Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007 0.93
14 Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage 2008 0.91
15 Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003 0.91
16 Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 2012 0.91
17 Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002 0.90
18 Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004 0.90
19 Patients' and relatives' perceptions about intravenous and subcutaneous hydration. J Pain Symptom Manage 2005 0.89
20 Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006 0.87
21 Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain 2006 0.87
22 Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002 0.87
23 Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. Curr Med Res Opin 2010 0.85
24 Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009 0.85
25 Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005 0.84
26 The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 2010 0.84
27 Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 2011 0.84
28 Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009 0.83
29 Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain 2009 0.82
30 Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006 0.82
31 Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003 0.81
32 Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin 2011 0.80
33 Local anesthetics for breakthrough pain in patients receiving intrathecal treatment for cancer pain management. Anesth Analg 2005 0.80
34 Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer 2006 0.80
35 Does pain intensity predict a poor opioid response in cancer patients? Eur J Cancer 2011 0.79
36 When the progression of disease lowers opioid requirement in cancer patients. Clin J Pain 2010 0.79
37 The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. Clin J Pain 2013 0.78
38 The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support Care Cancer 2010 0.78
39 Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage 2002 0.77
40 Refractory death rattle: deep aspiration facilitates the effects of antisecretory agents. J Pain Symptom Manage 2010 0.77
41 Prevalence of opioid-related dysuria in patients with advanced cancer having pain. Am J Hosp Palliat Care 2010 0.76
42 Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Clin J Pain 2009 0.76
43 The use of opioids in the last week of life in an acute palliative care unit. Am J Hosp Palliat Care 2010 0.75
44 Effectiveness and tolerability of amidotrizoate for the treatment of constipation resistant to laxatives in advanced cancer patients. J Pain Symptom Manage 2010 0.75
45 Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008 0.75
46 Switching from oxycodone to methadone in advanced cancer patients. Support Care Cancer 2011 0.75
47 Dialogues on complex analgesic strategies for difficult pain syndromes. Support Care Cancer 2004 0.75
48 Prolonged uncontrolled pain, psychological distress, and opioid escalation. J Pain Symptom Manage 2004 0.75
49 Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. J Palliat Med 2007 0.75
50 Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma. Breast Cancer Res Treat 2003 0.75
51 Switching from methadone to tapentadol for cancer pain. J Pain Symptom Manage 2012 0.75
52 Naloxone in treating central adverse effects during opioid titration for cancer pain. J Pain Symptom Manage 2003 0.75
53 Block of interdigital nerves for cancer pain. J Pain Symptom Manage 2002 0.75